These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 20425328)

  • 1. New agents in myelodysplastic syndromes.
    Jabbour E; Giles FJ
    Curr Hematol Malig Rep; 2006 Mar; 1(1):25-33. PubMed ID: 20425328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New agents in myelodysplastic syndromes.
    Jabbour EJ; Giles FJ
    Curr Hematol Rep; 2005 May; 4(3):191-9. PubMed ID: 15865871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating myelodysplastic syndromes.
    Ryan C; McCann S
    IDrugs; 2005 Apr; 8(4):320-6. PubMed ID: 15800807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for biology- and molecular-based treatment of myelodysplastic syndromes.
    Lindberg EH
    Curr Drug Targets; 2005 Sep; 6(6):713-25. PubMed ID: 16178803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug insight: emerging new drugs in the treatment of myelodysplastic syndromes.
    Faderl S; Kantarjian HM
    Nat Clin Pract Oncol; 2005 Jul; 2(7):348-55. PubMed ID: 16075794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease.
    Mohty R; Al Hamed R; Bazarbachi A; Brissot E; Nagler A; Zeidan A; Mohty M
    J Hematol Oncol; 2022 Aug; 15(1):124. PubMed ID: 36045390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New approaches to the treatment of myelodysplasia.
    List AF
    Oncologist; 2002; 7 Suppl 1():39-49. PubMed ID: 11961208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelodysplastic syndromes: From pathogenesis and prognosis to treatment.
    Fenaux P
    Semin Hematol; 2004 Apr; 41(2 Suppl 4):6-12. PubMed ID: 15190510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel therapies for myelodysplastic syndromes.
    Faderl S; Kantarjian HM
    Cancer; 2004 Jul; 101(2):226-41. PubMed ID: 15241818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic spectrum in the treatment of myelodysplastic syndromes.
    Hofmann WK; Baldus C; Uharek L; Thiel E
    Expert Opin Pharmacother; 2004 Dec; 5(12):2451-8. PubMed ID: 15571463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging drugs for the treatment of myelodysplastic syndrome.
    Nivatpumin PJ; Gore SD
    Expert Opin Emerg Drugs; 2005 Aug; 10(3):569-90. PubMed ID: 16083330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
    Vigna E; Recchia AG; Madeo A; Gentile M; Bossio S; Mazzone C; Lucia E; Morabito L; Gigliotti V; Stefano LD; Caruso N; Servillo P; Franzese S; Fimognari F; Bisconte MG; Gentile C; Morabito F
    Expert Opin Investig Drugs; 2011 Apr; 20(4):465-93. PubMed ID: 21381982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving therapies for lower-risk myelodysplastic syndromes.
    Bewersdorf JP; Zeidan AM
    Ann Hematol; 2020 Apr; 99(4):677-692. PubMed ID: 32078008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk-based management of myelodysplastic syndrome.
    Steensma DP; Tefferi A
    Oncology (Williston Park); 2007 Jan; 21(1):43-54; discussion 57-8, 62. PubMed ID: 17313156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes.
    Abou Zahr A; Saad Aldin E; Barbarotta L; Podoltsev N; Zeidan AM
    Expert Rev Anticancer Ther; 2015; 15(9):1019-36. PubMed ID: 26292903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recent advances in the treatment of myelodysplastic syndromes].
    Gelsi-Boyer V; Vey N
    Rev Med Interne; 2006 Aug; 27(8):600-9. PubMed ID: 16713027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agents.
    Hellström-Lindberg E
    Hematology Am Soc Hematol Educ Program; 2005; ():161-6. PubMed ID: 16304375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes.
    Stankov K; Stankov S; Katanic J
    Curr Pharm Des; 2017; 23(1):135-169. PubMed ID: 27697023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelodysplasia: new approaches.
    Seiter K
    Curr Treat Options Oncol; 2013 Jun; 14(2):156-69. PubMed ID: 23436197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More is better: combination therapies for myelodysplastic syndromes.
    Ornstein MC; Mukherjee S; Sekeres MA
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):22-31. PubMed ID: 25659727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.